Aripiprazole, 7-{4-\[4-(2,3-dichlorophenyl)-1-piperazinyl\]butyloxy}-3,4-dihydro-2(1H)-quinolinone, is an atypical antipsychotic. It is approved for the treatment of bipolar I disorder (in children aged 10-17 yr), schizophrenia (in children aged 13-17 yr)[@ref1] and autism in children and adolescents[@ref2] by the Food and Drug Administration (FDA). There is strong evidence for its efficacy for treating tic disorder[@ref3][@ref4]. In addition, there is some weak evidence for its efficacy for treating attention deficit hyperactivity disorder (ADHD)[@ref5]. It is a partial agonist of serotonin (5-hydroxy tryptamine, 5-HT) 5-HT1A[@ref6] and dopamine D2 receptors[@ref7]. It is also a 5-HT2A receptor antagonist without considerable affinity at the cholinergic muscarinic receptor[@ref2]. Its serum half-life in adults is 72 h. Aripirprazole has only one active metabolite, dehydroaripiprazole. The half-life of this metabolite is about 94 hours in adults[@ref8].

Autism is a complex neurodevelopmental disorder and its aetiology is not clearly known. At present, two medications including risperidone and aripiprazole are FDA approved for treatment of symptoms associated with autism[@ref2]. A 14-week, prospective, open-label study including 25 children with irritability and pervasive developmental disorder not otherwise specified and Asperger\'s disorder reported that aripiprazole had no significant cardiac effects[@ref9].

The aim of this systematic review was to evaluate the evidence from clinical trials of therapeutic intervention testing aripiprazole for autism in children and adolescents. A systematic review was conducted in May 2011 to determine the safety and efficacy of aripiprazole for patients with autism spectrum disorders (ASD)[@ref10]. This study found two randomized controlled trials using aripiprazole for a duration of eight weeks to treat autism in children.

There was no study conducted on adult patients with autism. It was found that aripiprazole improved irritability in children with autism, but increased weight more than placebo[@ref9]. The current systematic review was aimed to update the evidence for administering aripiprazole for treating autism.

Material & Methods {#sec1-1}
==================

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol was used to perform this systematic review[@ref11].

*Search strategy*: Systematic literature searches were conducted to retrieve all randomized clinical trials (RCTs) of aripiprazole for treating pervasive developmental disorder. The databases of MEDLINE, Google Scholar, The Cochrane Library and Web of Science were searched upto 2013. The International Clinical Trials Registry Platform was also searched to find currently ongoing trials.

The terms for conducting the search were "aripiprazole+pervasive developmental disorder", "autism+aripiprazole", and "autistic disorder+aripiprazole". Potentially relevant titles were selected and articles retrieved. A preliminary selection based on the titles was conducted. The references of the articles were also searched to find possible relevant articles. No language limitation was imposed.

*Study inclusion criteria*: All the randomized controlled clinical trials that investigated the effect of aripiprazole on irritability in pervasive developmental disorders were included. There were no age, publication date, and gender limitations. Any trial using a valid and reliable measurement to assess irritability was included. Intent-to-treat analysis was not an exclusion criterion.

*Evaluation of validity*: Methodological issues such as method of randomization, blinding of participants, and having any controlled groups were considered.

*Data extraction*: An extraction data sheet was designed. Study design, sampling, intervention, and adverse effects were extracted.

Results {#sec1-2}
=======

The number of identified articles was 93 ([Figure](#F1){ref-type="fig"}). Of these, 26 were found to be irrelevant. These studies had not examined the effect of aripiprazole on irritability in autism. The other reasons for exclusion were as follows: not a clinical trial[@ref10][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38], not double blind trials[@ref37][@ref39][@ref40][@ref41][@ref42], post-hoc analyses[@ref43][@ref44][@ref45], no control group[@ref46], case reports[@ref47][@ref48][@ref49][@ref50][@ref51][@ref52][@ref53][@ref54][@ref55], switching risperidone to aripiprazole[@ref56][@ref57], data re-analysis[@ref58], assessed body mass index changes[@ref59], prevention of irritability[@ref60], and retrospective studies[@ref61][@ref62][@ref63][@ref64][@ref65]. One study reported anti-manic effect of aripiprazole in patients with autism spectrum disorder and bipolar disorder[@ref66]. Another reported lack of any significant effect of aripiprazole on electrocardiographic data in paediatric patients[@ref9]. A post-hoc analysis reported quality of life of children with autism[@ref44].

![Flowchart of trial selection process.](IJMR-142-269-g001){#F1}

Only five articles met the inclusion criteria[@ref67][@ref68][@ref69][@ref70][@ref71]. In these trials, the effect of aripiprazole on patients with autism was investigated. The details of these studies are indicated in the [Table](#T1){ref-type="table"}. Only one trial compared the safety and efficacy of aripiprazole with another antipsychotic, risperidone, for treating children with autism[@ref71].

###### 
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Only one systematic review was found concerning the effect of aripiprazole for treating autism in the Cochrane Library published in 2012[@ref10]. Searching Web of Science retrieved 83 titles, but these did not add to the titles retrieved from the two databases of PubMed/MEDLINE and Google Scholar.

*In progress unpublished studies*: There was one unpublished study in progress about the effect of aripiprazole for treating autism (NCT02069977) and there were two other studies that had not started recruiting patients yet (NCT00468130, and NCT00208533).

Discussion {#sec1-3}
==========

In this systematic review, five published studies on the effect of aripiprazole on autism were reviewed. The best evidence from the randomized placebo controlled clinical trials confirmed that aripiprazole more than placebo reduced irritability in autism. The efficacy and safety of aripiprazole were comparable to risperidone for treating children and adolescents with autism[@ref71]. All these studies included children and adolescents. Therefore, it is not clear whether these results can be generalized to adult individuals with autism. This systematic review of double-blind controlled RCTs showed convincing evidence of effectiveness and, therefore, supported the recommendations for the use of aripiprazole for treating irritability associated with autism. Other reviews that included open label or retrospective trials also have shown similar results.

Regarding side effects, aripiprazole in children and adolescents seemed to be safe. Many of the adverse effects reported were of mild nature. Serious adverse effects were rare. Because, the number of RCTs is very limited, larger studies need to be conducted to show if it is totally safe. One of the limitations of this review is potential incompleteness of the reviewed evidence. Publication bias cannot be ignored. The four major databases of PubMed/MEDLINE, Google Scholar, the Cochrane Library, and Web of Science were searched. In addition, we also searched International Clinical Trials Registry Platform to find ongoing trials.

In conclusion, the current evidences support the efficacy and safety of aripiprazole for treating irritability in autism in children and adolescents.
